165 related articles for article (PubMed ID: 10999488)
21. Modulation of eotaxin formation and eosinophil migration by selective inhibitors of phosphodiesterase type 4 isoenzyme.
Silva PM; Alves AC; Serra MF; Pires AL; Silva JP; Barreto EO; Cordeiro RS; Jose PJ; Teixeira MM; Lagente V; Martins MA
Br J Pharmacol; 2001 Sep; 134(2):283-94. PubMed ID: 11564646
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
[TBL] [Abstract][Full Text] [Related]
23. Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors.
Méhats C; Tanguy G; Paris B; Robert B; Pernin N; Ferré F; Leroy MJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):817-23. PubMed ID: 10640323
[TBL] [Abstract][Full Text] [Related]
24. Substituted furans as inhibitors of the PDE4 enzyme.
Perrier H; Bayly C; Laliberté F; Huang Z; Rasori R; Robichaud A; Girard Y; Macdonald D
Bioorg Med Chem Lett; 1999 Feb; 9(3):323-6. PubMed ID: 10091677
[TBL] [Abstract][Full Text] [Related]
25. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
[TBL] [Abstract][Full Text] [Related]
26. The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.
Hulme C; Moriarty K; Miller B; Mathew R; Ramanjulu M; Cox P; Souness J; Page KM; Uhl J; Travis J; Huang FC; Labaudiniere R; Djuric SW
Bioorg Med Chem Lett; 1998 Jul; 8(14):1867-72. PubMed ID: 9873449
[TBL] [Abstract][Full Text] [Related]
27. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
28. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological studies of catechol ether type derivatives as potential phosphodiesterase (PDE) IV inhibitors.
Rhee CK; Kim JH; Suh BC; Xiang MX; Youn YS; Bang WY; Kim E; Shin JK; Lee Y
Arch Pharm Res; 1999 Apr; 22(2):202-7. PubMed ID: 10230513
[TBL] [Abstract][Full Text] [Related]
30. Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.
Ducharme Y; Friesen RW; Blouin M; Côté B; Dubé D; Ethier D; Frenette R; Laliberté F; Mancini JA; Masson P; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2003 Jun; 13(11):1923-6. PubMed ID: 12749899
[TBL] [Abstract][Full Text] [Related]
31. Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.
Guay D; Hamel P; Blouin M; Brideau C; Chan CC; Chauret N; Ducharme Y; Huang Z; Girard M; Jones TR; Laliberté F; Masson P; McAuliffe M; Piechuta H; Silva J; Young RN; Girard Y
Bioorg Med Chem Lett; 2002 Jun; 12(11):1457-61. PubMed ID: 12031319
[TBL] [Abstract][Full Text] [Related]
32. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
Souness JE; Maslen C; Webber S; Foster M; Raeburn D; Palfreyman MN; Ashton MJ; Karlsson JA
Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982
[TBL] [Abstract][Full Text] [Related]
33. A comparison of the inhibitory activity of selective PDE4 inhibitors on eosinophil recruitment in guinea pig skin.
Teixeira MM; Miotla JM; Cooper N; Gristwood RW; Hellewell PG
Mem Inst Oswaldo Cruz; 1997; 92 Suppl 2():193-6. PubMed ID: 9698932
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors.
Giovannoni MP; Cesari N; Graziano A; Vergelli C; Biancalani C; Biagini P; Dal Piaz V
J Enzyme Inhib Med Chem; 2007 Jun; 22(3):309-18. PubMed ID: 17674813
[TBL] [Abstract][Full Text] [Related]
35. Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
Bioorg Med Chem Lett; 2001 Jan; 11(1):33-7. PubMed ID: 11140727
[TBL] [Abstract][Full Text] [Related]
36. Suppression of anti-CD3-induced interleukin-4 and interleukin-5 release from splenocytes of Mesocestoides corti-infected BALB/c mice by phosphodiesterase 4 inhibitors.
Souness JE; Houghton C; Sardar N; Withnall MT
Biochem Pharmacol; 1999 Sep; 58(6):991-9. PubMed ID: 10509751
[TBL] [Abstract][Full Text] [Related]
37. N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
Bacher E; Boer C; Bray-French K; Demnitz FW; Keller TH; Mazzoni L; Müller T; Walker C
Bioorg Med Chem Lett; 1998 Nov; 8(22):3229-34. PubMed ID: 9873708
[TBL] [Abstract][Full Text] [Related]
38. 4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered?
Giembycz MA
Trends Pharmacol Sci; 2002 Dec; 23(12):548. PubMed ID: 12457768
[No Abstract] [Full Text] [Related]
39. Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
Nam G; Yoon CM; Kim E; Rhee CK; Kim JH; Shin JH; Kim SH
Bioorg Med Chem Lett; 2001 Mar; 11(5):611-4. PubMed ID: 11266153
[TBL] [Abstract][Full Text] [Related]
40. Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.
Charpiot B; Brun J; Donze I; Naef R; Stefani M; Mueller T
Bioorg Med Chem Lett; 1998 Oct; 8(20):2891-6. PubMed ID: 9873643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
